Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan plus high-dose amoxicillin dual therapy for Helicobacter pylori infection
ChiCTR2200062264Phase 4Not yet recruiting
- Sponsor
- Xuzhou No. 1 People's Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of vonoprazan and amoxicillin in Helicobacter pylori infection (4 arms), sponsored by Xuzhou No. 1 People's Hospital. Primary endpoint: Helicobacter pylori eradication status at 28 days after treatment. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
vonoprazanamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2200062264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062264.